Market Overview:
The global human immune globulin intravenous (IVIg) market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of immunodeficiency, autoimmune diseases, and acute infections across the globe. Additionally, rising demand for IVIg products from emerging countries is also contributing to the growth of this market. Based on type, the global human immune globulin intravenous (IVIg) market has been segmented into IVIg liquid and IVIg powder. The IVIg liquid segment is expected to account for a larger share of the global market in 2018. This can be attributed to its ease of use and higher efficacy as compared to other types of products available in this category. Based on application, the global human immune globulin intravenous (IVG)market has been segmented into immunodeficiency disorders, autoimmune diseases such as rheumatoid arthritis and Crohn’s disease), acute infections such as sepsis and pneumonia), transplantation rejection prophylaxis), neurologic disorders such as multiple sclerosis).and Guillain-Barre Syndrome).
Product Definition:
Human Immune Globulin Intravenous (HIGIV) is a blood product that is used to increase the level of antibodies in people who have low levels of these antibodies. These antibodies are important for protecting the body from infection. HIGIV is given by injection into a vein.
IVIg Liquid:
IVIg Liquid is a ready-to-use intravenous immunoglobulin, which is manufactured in human plasma. It helps to fight against the immune system breakdown caused by various infectious diseases and medical conditions like cancer, infections etc. IVIG has been observed effective in treating life-threatening allergic reactions such as anaphylaxis.
IVIg Powder:
IVIg powder is a ready-to-use solution of human immunoglobulin made in a laboratory. It is used to treat immune deficiencies and certain types of cancer. IVIg powder can replace antibodies in the human body which helps fight against infections, inflammation, and other diseases caused by viruses or bacteria.
The global IVIg Powder.
Application Insights:
On the basis of application, the global human immune globulin intravenous (IV) market is segmented into immunodeficiency diseases, autoimmune disease, and acute infection. The immunodeficiency diseases segment dominated the overall market in terms of revenue share in 2017 owing to a high incidence rate of HIV infection coupled with unmet medical needs for IVIG therapy worldwide.
The autoimmune disease segment is expected to witness lucrative growth over the forecast period due to an increase in prevalence rates for rheumatoid arthritis and lupus globally coupled with unmet clinical needs for IVIG treatment across these disorders. Acute infections are also likely to exhibit significant demand owing to a rise in hospital admissions for bacterial and viral infections across all regions including North America, Europe, Asia Pacific Latin America Middle East & Africa which may require IVIG as a part-of-care or full course antibiotic treatment depending on severity of illness.
Regional Analysis:
North America dominated the global market in 2017 owing to a rise in cases of immune disorders and an increase in R&D initiatives by major players. In addition, increasing government funding for research activities pertaining to human immune globulin intravenous is also expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period due to rising incidences of autoimmune diseases coupled with growing healthcare expenditure levels in emerging economies such as India and China. Moreover, a rise in awareness about IVIg treatment among patients from these countries will propel demand further.
Growth Factors:
- Increasing incidence of autoimmune diseases: The global prevalence of autoimmune diseases is increasing at a significant rate. This is primarily attributed to the changing lifestyle and environmental factors. The human immune globulin intravenous market is expected to benefit from this trend as it offers an effective treatment for various autoimmune disorders.
- Growing demand for immunoglobulins: Immunoglobulins are proteins that play a crucial role in the body’s immune system by protecting against infection and disease. There is a growing demand for immunoglobulins across the globe, which is expected to drive the growth of the human immune globulin intravenous market in coming years.
- Technological advancements: The human immune globulin intravenous market has witnessed several technological advancements in recent years, which has led to improved efficacy and safety profiles of these products. This is likely to boost the adoption of human immune globulin intravenous products among patients worldwide in coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Immune Globulin Intravenous Market Research Report
By Type
IVIg Liquid, IVIg Powder
By Application
Immunodeficiency, Autoimmune Disease, Acute Infection
By Companies
Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, Hualan Bio, CNBG, Shanghai RAAS, CBPO, LFB Group, BPL, Sichuan Yuanda Shuyang
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Human Immune Globulin Intravenous Market Report Segments:
The global Human Immune Globulin Intravenous market is segmented on the basis of:
Types
IVIg Liquid, IVIg Powder
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Immunodeficiency, Autoimmune Disease, Acute Infection
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxter
- Grifols
- CSL
- Octapharma
- Biotest
- Kedrion
- Hualan Bio
- CNBG
- Shanghai RAAS
- CBPO
- LFB Group
- BPL
- Sichuan Yuanda Shuyang
Highlights of The Human Immune Globulin Intravenous Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- IVIg Liquid
- IVIg Powder
- By Application:
- Immunodeficiency
- Autoimmune Disease
- Acute Infection
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Immune Globulin Intravenous Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human immune globulin intravenous (HIV) is a type of medication used to treat HIV infection. It helps the body fight off infections by providing antibodies.
Some of the major players in the human immune globulin intravenous market are Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, Hualan Bio, CNBG, Shanghai RAAS, CBPO, LFB Group, BPL, Sichuan Yuanda Shuyang.
The human immune globulin intravenous market is expected to register a CAGR of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Immune Globulin Intravenous Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Immune Globulin Intravenous Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Immune Globulin Intravenous Market - Supply Chain
4.5. Global Human Immune Globulin Intravenous Market Forecast
4.5.1. Human Immune Globulin Intravenous Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Immune Globulin Intravenous Market Size (000 Units) and Y-o-Y Growth
4.5.3. Human Immune Globulin Intravenous Market Absolute $ Opportunity
5. Global Human Immune Globulin Intravenous Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Human Immune Globulin Intravenous Market Size and Volume Forecast by Type
5.3.1. IVIg Liquid
5.3.2. IVIg Powder
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Human Immune Globulin Intravenous Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Human Immune Globulin Intravenous Market Size and Volume Forecast by Application
6.3.1. Immunodeficiency
6.3.2. Autoimmune Disease
6.3.3. Acute Infection
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Human Immune Globulin Intravenous Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Human Immune Globulin Intravenous Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Human Immune Globulin Intravenous Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Human Immune Globulin Intravenous Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Human Immune Globulin Intravenous Demand Share Forecast, 2019-2026
9. North America Human Immune Globulin Intravenous Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Human Immune Globulin Intravenous Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Human Immune Globulin Intravenous Market Size and Volume Forecast by Application
9.4.1. Immunodeficiency
9.4.2. Autoimmune Disease
9.4.3. Acute Infection
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Human Immune Globulin Intravenous Market Size and Volume Forecast by Type
9.7.1. IVIg Liquid
9.7.2. IVIg Powder
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Human Immune Globulin Intravenous Demand Share Forecast, 2019-2026
10. Latin America Human Immune Globulin Intravenous Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Human Immune Globulin Intravenous Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Human Immune Globulin Intravenous Market Size and Volume Forecast by Application
10.4.1. Immunodeficiency
10.4.2. Autoimmune Disease
10.4.3. Acute Infection
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Human Immune Globulin Intravenous Market Size and Volume Forecast by Type
10.7.1. IVIg Liquid
10.7.2. IVIg Powder
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Human Immune Globulin Intravenous Demand Share Forecast, 2019-2026
11. Europe Human Immune Globulin Intravenous Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Human Immune Globulin Intravenous Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Human Immune Globulin Intravenous Market Size and Volume Forecast by Application
11.4.1. Immunodeficiency
11.4.2. Autoimmune Disease
11.4.3. Acute Infection
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Human Immune Globulin Intravenous Market Size and Volume Forecast by Type
11.7.1. IVIg Lquid
11.7.2. IVIg Powder
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Human Immune Globulin Intravenous Demand Share, 2019-2026
12. Asia Pacific Human Immune Globulin Intravenous Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Human Immune Globulin Intravenous Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Human Immune Globulin Intravenous Market Size and Volume Forecast by Application
12.4.1. Immunodeficiency
12.4.2. Autoimmune Disease
12.4.3. Acute Infection
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Human Immune Globulin Intravenous Market Size and Volume Forecast by Type
12.7.1. IVIg Liquid
12.7.2. IVIg Powder
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Human Immune Globulin Intravenous Demand Share, 2019-2026
13. Middle East & Africa Human Immune Globulin Intravenous Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Human Immune Globulin Intravenous Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Human Immune Globulin Intravenous Market Size and Volume Forecast by Application
13.4.1. Immunodeficiency
13.4.2. Autoimmune Disease
13.4.3. Acute Infection
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Human Immune Globulin Intravenous Market Size and Volume Forecast by Type
13.7.1. IVIg Liquid
13.7.2. IVIg Powder
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Human Immune Globulin Intravenous Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Human Immune Globulin Intravenous Market: Market Share Analysis
14.2. Human Immune Globulin Intravenous Distributors and Customers
14.3. Human Immune Globulin Intravenous Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Baxter
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Grifols
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. CSL
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Octapharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Biotest
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Kedrion
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Hualan Bio
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. CNBG
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Shanghai RAAS
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. CBPO
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. LFB Group
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. BPL
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Sichuan Yuanda Shuyang
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
